PMC:7247521 / 6440-6979
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 113 | 32-35 | Disease | denotes | XCH | |
| 114 | 94-120 | Disease | denotes | viral infectious pneumonia | |
| 115 | 307-315 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T80 | 94-99 | NCBITaxon:10239 | denotes | viral |
| T81 | 170-179 | CHEBI:36357;CHEBI:36357 | denotes | compounds |
| T82 | 307-315 | SP_7 | denotes | COVID-19 |
| T83 | 355-367 | CHEBI:52217;CHEBI:52217 | denotes | pharmacology |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T31 | 100-110 | Disease | denotes | infectious | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T32 | 111-120 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
| T33 | 307-315 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T49 | 237-238 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T50 | 319-320 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T51 | 432-433 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T52 | 516-517 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T9 | 111-120 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T41 | 0-220 | Sentence | denotes | In our study, since MSXG, SGMH, XCH and WLS have been independently used for the treatment of viral infectious pneumonia, this study firstly screened out major effective compounds from five functional units respectively. |
| T42 | 221-539 | Sentence | denotes | Then we offered a new understanding of the functional units mechanism of QFPD against COVID-19 by a novel functional units of network pharmacology (FUNP) approach and formula perturbation analysis, and provided a combination strategy to explore mechanisms of inter-ingredients interactions from a holistic perspective. |